Stay updated on Phase 1 Study CI-8993 Anti-VISTA Antibody Clinical Trial
Sign up to get notified when there's something new on the Phase 1 Study CI-8993 Anti-VISTA Antibody Clinical Trial page.

Latest updates to the Phase 1 Study CI-8993 Anti-VISTA Antibody Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check51 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check65 days agoChange DetectedThe web page has been updated to reflect a new version of the study protocol for CI-8993, including changes to the administration process and safety review criteria for patients with solid tumors. Key details about the study's design and patient eligibility criteria have been removed.SummaryDifference40%
Stay in the know with updates to Phase 1 Study CI-8993 Anti-VISTA Antibody Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1 Study CI-8993 Anti-VISTA Antibody Clinical Trial page.